Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Study Details
Study Description
Brief Summary
The study is a phase 2/3, multicenter, double-blind, parallel assignment study. It involves 100 adult recipients of an intra-hepatic pancreatic Islet Auto-Transplantation (IAT).
The objective of this clinical trial is to assess whether reparixin leads to improved transplant outcome as measured by the proportion of insulin-independent patients following IAT. The safety of reparixin in the specific clinical setting will be also evaluated.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2/Phase 3 |
Detailed Description
In contrast to allo-transplantation in type 1 diabetes patients, where immunological mechanisms involving allo- and auto-antibodies affect long-term graft function, outcome in IAT (Islet Auto-Transplantation) is independent from immunological processes and does not require immunosuppression management. On the other hand, early inflammatory events intrinsic to the intra-portal islet infusion have been demonstrated to impact islet engraftment. Among possible mechanisms, PMNs have been found to be the predominant cell types infiltrating the liver in a syngeneic model of islet transplantation in mice.
Data obtained in experimental models of islet transplantation in mice demonstrate a clear effect of reparixin in improving graft survival and function. Protection from the loss and/or deterioration of transplanted islets was evident regardless of the immunological mechanisms involved in islet damage, suggesting that the ability of reparixin to modulate early inflammatory responses readily impact graft outcome.
Thus, the use of reparixin may emerge as a potential useful medication in the control of non specific inflammatory events surrounding the early phases of IAT.
The goal of this study is to reach a total of 100 adult patients who are randomized and receive IAT after total or completion pancreatectomy. Patients will be randomly (1:1) assigned to receive either reparixin [continuous i.v. infusion for 7 days (168hrs)], or matched placebo (control group),starting approximately 12hrs before islet infusion. The two groups will be balanced within each centre. All patients who are randomized and receive the Investigational Product (either reparixin or placebo) will be included in the ITT analysis. Patients will be in the ITT analysis whether or not they receive IAT, because exclusions cannot be made for events occurring after randomization that could be influenced by the randomized assignment.
Recruitment will be competitive among the study sites, until the planned number of patients is enrolled. Competitive recruitment has been chosen to increase the speed of recruitment and to account for any difference in transplant rate among study sites. Each centre will enroll patients as rapidly as possible, up to a maximum of 40 patients (as per the randomization list). A maximum of 48 patients is allowed for the site of the Primary Investigator.
Each patient will be involved in the study for 7 day hospital stay during pancreatectomy followed by islet transplantation, for all required measurements up to hospital discharge and for 2 post-transplant visits scheduled @ day 75+14 and 365+14 after the transplant.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Reparixin Solution for intravenous (IV) infusion with active compound |
Drug: Reparixin
Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour
Other Names:
|
| Placebo Comparator: Placebo Physiologic solution |
Drug: Placebo
Physiologic solution administered at 0.25 mL/kg/hour
|
Outcome Measures
Primary Outcome Measures
- Percentage of Patients Who Were Insulin Independent After Islet Autotransplantation (IAT) at Day 365±14 Days After Transplant. [day 365±14 after the transplant]
Insulin-independence is defined as freedom from the need to take exogenous insulin for 14 or more consecutive days, with adequate glycemic control, as defined by: a glycated hemoglobin (HbA1c) level <6.5%; fingerstick fasting blood glucose not exceeding 126 mg/dL more than three times in the past week (based on a minimum of one daily measurement; a 2 hour post-prandial blood glucose not exceeding 180 mg/dL more than four times in the past week (based on a minimum of one daily measurement); a laboratory fasting glucose in the non-diabetic range (<126 mg/dL).
Secondary Outcome Measures
- Area Under the Curve (AUC) for the Serum C-peptide Level at Day 75±14 After the Transplant [day 75±14 after the transplant]
AUC for the serum C-peptide level is calculated during the first 4 hours of an MMTT, normalized by the number of Islet Equivalent (IEQ)/kg
- Area Under the Curve (AUC) for the Serum C-peptide Level at Day 365±14 After the Transplant [day 365±14 after the transplant]
AUC for the serum C-peptide level is calculated during the first 4 hours of a mixed meal tolerance test (MMTT), normalized by the number of Islet Equivalent (IEQ)/kg
- Average Daily Insulin Requirements at Day 75±14 After the Transplant [day 75±14 after the transplant]
Daily insulin is reported as IU/kg and intake averaged over the previous week.
- Average Daily Insulin Requirements at Day 365±14 After the Transplant [day 365±14 after the transplant]
Daily insulin is reported as IU/kg and intake averaged over the previous week.
- Time Course From Basal to 240 Min of Glucose Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant [day 75±14 after the transplant]
Data of this outcome are reported as "model estimates over all timepoints". This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=43; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal). 15 min; N=42; 46 30 min; N=40; 46 60 min; N=40; 46 90 min; N=40; 46 120 min; N=41; 46 180 min; N=40; 46 240 min; N=39; 44
- Time Course From Basal to 240 Min of Glucose Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant [day 365±14 after the transplant]
Data are reported as "model estimates over all timepoints" This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=34; 42 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal). 15 min; N=34; 41 30 min; N=34; 41 60 min; N=34; 41 90 min; N=34; 41 120 min; N=34; 41 180 min; N=33; 41 240 min; N=33; 41
- Time Course From Basal to 240 Min of C-peptide Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant [day 75±14 after the transplant]
Data are reported as "model estimates over all timepoints". This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=44; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal). 15 min; N=43; 47 30 min; N=41; 47 60 min; N=42; 47 90 min; N=42; 47 120 min; N=42; 47 180 min; N=41; 47 240 min; N=40; 44
- Time Course From Basal to 240 Min of C-peptide Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant [day 365±14 after the transplant]
Data are reported as "model estimates over all timepoints". This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=33; 41 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal). 15 min; N=34; 41 30 min; N=34; 41 60 min; N=33; 41 90 min; N=34; 41 120 min; N=34; 41 180 min; N=33; 40 240 min; N=33; 41
- Time Course From Basal to 240 Min of Insulin Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant [day 75±14 after the transplant]
Data are reported as "model estimates over all timepoints". This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=43; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal). 15 min; N=43; 47 30 min; N=41; 47 60 min; N=41; 47 90 min; N=41; 47 120 min; N=42; 47 180 min; N=41; 47 240 min; N=40; 44
- Time Course From Basal to 240 Min of Insulin Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant [day 365±14 after the transplant]
Data are reported as "model estimates over all timepoints". This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=34; 41 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal) 15 min; N=34; 41 30 min; N=34; 41 60 min; N=34; 41 90 min; N=34; 41 120 min; N=34; 41 180 min; N=33; 41 240 min; N=33; 40
- β-cell Function at Day 75±14 After the Transplant [day 75±14 after the transplant]
This variable is assessed by β-score (assessment of β-cell function after islet transplantation). The total score is calculated on a 0-8 scoring system (higher is a better outcome) that gives 0-2 points each for: fasting plasma glucose, HbA1c, stimulated C-peptide insulin requirement subscales. The higher the total score, the better the outcome. Fasting (or before breakfast) plasma glucose (mg/dL) : ≤99, Score 2; 100-124, Score 1; ≥ 125, Score 0 (the higher the subscore the better the outcome) HbA1c (%): ≤6.1, Score 2; 6.2-6.9, Score 1; ≥ 7.0, Score 0 (the higher the subscore the better the outcome) Daily average (previous week) insulin (IU/kg/day): ---, Score 2; 0.01-0.24, Score 1; ≥ 0.25, Score 0 (the higher the subscore the better the outcome) Stimulated C-peptide (ng/mL): ≥ 0.9, Score 2; 0.3-0.89, Score 1; ≤0.3, Score 0 (the higher the subscore the better the outcome)
- β-cell Function at Day 365±14 After the Transplant [day 365±14 after the transplant]
This variable is assessed by β-score (assessment of β-cell function after islet transplantation). The total score is calculated on a 0-8 scoring system (higher is a better outcome) that gives 0-2 points each for glucose, HbA1c, stimulated C-peptide and insulin requirement subscales. The higher the total score the better the outcome. Fasting (or before breakfast) plasma glucose (mg/dL) : ≤99, Score 2; 100-124, Score 1; ≥ 125, Score 0 (the higher the subscore the better the outcome) HbA1c (%): ≤6.1, Score 2; 6.2-6.9, Score 1; ≥ 7.0, Score 0 (the higher the subscore the better the outcome) Daily average (previous week) insulin (IU/kg/day): ---, Score 2; 0.01-0.24, Score 1; ≥ 0.25, Score 0 (the higher the subscore the better the outcome) Stimulated C-peptide (ng/mL): ≥ 0.9, Score 2; 0.3-0.89, Score 1; ≤0.3, Score 0 (the higher the subscore the better the outcome)
- Proportion of Patients With an HbA1c <6.5% at Day 365±14 After the Transplant [day 365±14 after the transplant]
Percentage of patients with a glycated haemoglobin (HbA1c) <6.5% at day 365±14 after the transplant.
- Cumulative Number of Severe Hypoglycemic Events From Day 75±14 to Day 365±14 After the Transplant [from day 75±14 to day 365±14 after the transplant]
A severe hypoglycemic event is defined as an event with one of the following symptoms: "memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms", in which the subject was unable to treat him/herself and which was associated with either a blood glucose level <54mg/dL or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration.
- Proportion of Patients With an HbA1c <6.5% at Day 365±14 After the Transplant AND Free of Severe Hypoglycemic Events From Day 75±14 to Day 365±14 After the Transplant Inclusive [from day 75±14 to day 365±14 after the transplant]
Percentage of patients with an HbA1c <6.5% at day 365±14 after the transplant AND free of severe hypoglycemic events from day 75±14 to day 365±14 after the transplant inclusive.A severe hypoglycemic event is defined as an event with one of the following symptoms: "memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms", in which the subject was unable to treat him/herself and which was associated with either a blood glucose level <54mg/dL or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration.
- Incidence and Severity of Adverse Events and Serious Adverse Events Throughout the Study [up to day 365±14 after the transplant]
The percentages of patients with any treatment emergent adverse events (TEAE, serious and non serious) and with serious TEAE by severity are presented. Patients with multiple events within a particular system organ class or preferred term were counted only under the category of their most severe event within that system organ class or preferred term. A serious AE was defined as any untoward medical occurrence that at any dose: Resulted in death Was life-threatening (ie, the patient was at risk of death at the time of the event) Required inpatient hospitalization or prolongation of existing hospitalization Resulted in persistent or significant disability/incapacity Was a congenital anomaly/birth defect Was an important medical event that, based upon appropriate medical judgment, may have jeopardized the patient and may have required medical or surgical intervention to prevent one of the outcomes listed above
- Proportion of Patients Falling Into One of the Following Malnutrition Risk Levels (Poor Prognosis, Significant Risk, Increased Risk, Normal) According to Pre-albumin Level at Day 75±14 After the Transplant [day 75±14 after the transplant]
Malnutrition risk levels are defined as: Poor prognosis = pre-albumin level <5.0 mg/dL Significant risk = pre-albumin level 5.0 to 10.9 mg/dL Increased risk = pre-albumin level 11.0 to 15.0 mg/dL Normal = pre-albumin level > 15.0 (up to 35.0) mg/dL
- Proportion of Patients Falling Into One of the Following Malnutrition Risk Levels (Poor Prognosis, Significant Risk, Increased Risk, Normal) According to Pre-albumin Level at Day 365±14 After the Transplant [day 365±14 after the transplant]
Malnutrition risk levels are defined as: Poor prognosis = pre-albumin level <5.0 mg/dL Significant risk = pre-albumin level 5.0 to 10.9 mg/dL Increased risk = pre-albumin level 11.0 to 15.0 mg/dL Normal = pre-albumin level > 15.0 (up to 35.0) mg/dL
- Proportion of Patients by Steatorrhea Severity at Day 75±14 After the Transplant [day 75±14 after the transplant]
Levels of steatorrhea severity (evaluated in the 4 weeks prior to day 75±14 and 365±14), are defined as: No steatorrhea; Steatorrhea few times per week; Steatorrhea daily; Stool incontinence.
- Proportion of Patients by Steatorrhea Severity at Day 365±14 After the Transplant [day 365±14 after the transplant]
Levels of steatorrhea severity (evaluated in the 4 weeks prior to day 75±14 and 365±14), are defined as: No steatorrhea; Steatorrhea few times per week; Steatorrhea daily; Stool incontinence.
- Cumulative Number of Episodes of Documented Asymptomatic Hypoglycemia From Day 75±14 to Day 365±14 After the Transplant [from day 75±14 to day 365±14 after the transplant]
The following definition applies: - Asymptomatic hypoglycemia = An event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration <70mg/dL.
- Cumulative Number of Episodes of Documented Symptomatic Hypoglycemia From Day 75±14 to Day 365±14 After the Transplant [from day 75±14 to day 365±14 after the transplant]
The following definition applies: - Documented symptomatic hypoglycemia = An event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration <70mg/dL.
- Cumulative Number of Diabetic Ketoacidosis-related Events [from day 75±14 to day 365±14 after the transplant]
A diabetic ketoacidosis event is defined as the presence of: hyperglycemia (blood glucose >200 mg/dL); pH <7.3 or HCO3 <15; ketones positive in the serum or urine.
- Peak C-peptide at Day 75 After the Transplant [Day 75±14 after the transplant]
Peak C-peptide (C-P) is a known predictor of Type 1 Diabetes.
- Peak C-peptide at Day 365 After the Transplant [Day 365±14 after the transplant]
Peak C-peptide (C-P) is a known predictor of Type 1 Diabetes.
- Time-to-peak C-peptide at Day 75 After the Transplant [day 75±14 and day 365±14 after the transplant]
The time-to-peak value in minutes was computed as the time of the peak value (HH:MM on a 24-hour clock) minus the end time of the mixed meal (HH:MM on a 24-hour clock) as recorded on the mixed meal tolerance test Case Report Form.
- Time-to-peak C-peptide at Day 365 After the Transplant [Day 365±14 after the transplant]
The time to peak value in minutes will be computed as the time of the peak value (HH:MM on a 24-hour clock) minus the end time of the mixed meal (HH:MM on a 24-hour clock) as recorded on the mixed meal tolerance test CRF.
- Change From Baseline in Post-transplant Alanine Aminotransferase (ALT) [Baseline, Days 2, 3, 7, 75 ±14 after the transplant]
Data are reported as "model estimates over all timepoints". This safety parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: baseline; N=50; 52 Day 2 post-transplant; N=49; 51 Day 3 post-transplant; N=47; 50 Day 7 post-transplant; N=47; 50 Day 75 post-transplant; N=44; 47
- Change From Baseline in Post-transplant Aspartate Aminotransferase (AST) [Baseline, Days 2, 3, 7, 75±14 after the transplant]
Data are reported as "model estimates over all timepoints". This safety parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: baseline; N=50; 52 Day 2 post-transplant; N=49; 51 Day 3 post-transplant; N=47; 50 Day 7 post-transplant; N=47; 50 Day 75 post-transplant; N=44; 47
- Number of Treatment Emergent Adverse Events Related to Investigational Product [Throughout the study From Day -1 to hospital discharge]
Treatment emergent adverse events - possibly, probably and highly probably - related to investigational product are called "Adverse reactions" (ADR). An adverse reaction is defined as any untoward medical occurrence in a patient or clinical investigation patient, which has a causal relationship with the administered medicinal product.
- Number of Serious Treatment Emergent Adverse Events Related to Investigational Product [Throughout the study From Day -1 to hospital discharge for all adverse events, and from then to day 365 post-transplantation only for serious adverse events]
Serious Treatment emergent adverse events - possibly, probably and highly probably - related to investigational product are called serious "Adverse reactions". A serious adverse reaction is defined as any untoward medical occurrence with a causal relationship with the administered medicinal product, that at any dose: Resulted in death Was life-threatening (ie, the patient was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.) Required patient hospitalization or prolongation of existing hospitalization Resulted in persistent or significant disability/incapacity Was an important medical event that, based upon appropriate medical judgment, may have jeopardized the patient and may have required medical or surgical intervention to prevent one of the outcomes listed above
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients eligible for an IAT following total (or completion) pancreatectomy.
-
Ages > 18 years.
-
Patients willing and able to comply with the protocol procedures for the duration of the study, including scheduled follow-up visits and examinations.
-
Patients who have given written informed consent, prior to any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
Exclusion Criteria:
-
Recipients of a previous IAT (if completion pancreatectomy).
-
Patients undergoing total pancreatectomy due to either pancreatic cancer or pancreatic benign diseases other than chronic pancreatitis, including insulinomas, etc.
-
Patients with inadequate renal reserve as per calculated creatinine clearance (CLcr) < 60 mL/min according to the Cockcroft-Gault formula (1976).
-
Patients with hepatic dysfunction as defined by increased ALT/AST > 3 x upper limit of normal (ULN) or increased total bilirubin above the upper limit at local laboratory). Patients with Gilbert's syndrome (elevated unconjugated bilirubin levels in the absence of any evidence of hepatic or biliary tract disease) are not excluded.
-
Patients with a preoperative International Normalized Ratio (INR) > 1.5 or any known coagulopathy.
-
Hypersensitivity to:
-
ibuprofen or to more than one non steroidal anti-inflammatory drug (NSAID).
-
medications belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib.
-
Concurrent sepsis (as per positive blood culture(s) and/or fever associated with other signs of systemic sepsis syndrome).
-
Treatment with systemic steroids in the 2 weeks prior to enrolment (except for the use of <5mg prednisone daily or equivalent dose of hydrocortisone, for physiological replacement only) or with any immune modulators in the 4 weeks prior to enrolment.
-
Patients with pre-existing diabetes or evidence of impaired β-cells function, based on pre-operative fasting blood glucose >115 mg/dL and/or a HbA1c > 6.5%, or requiring treatment with any anti-diabetic medication (e.g. insulin, metformin, etc) within the 2 weeks prior to enrolment.
-
Use of any investigational agent in the 4 weeks prior to enrolment, including any anti-cytokine/chemokine agents.
-
Pregnant or breast-feeding women; unwillingness to use effective contraceptive measures (females and males). (NB: pregnancy should be avoided in patients or partners during the first month after completing the treatment with the Investigational Product; no other specific warnings are described, considering the treatment course of the Investigational Product, its PK profile, and the lack of significant adverse effects on mating performance and fertility in animal studies).
-
Patients with past or current history of alcohol abuse based on clinical history and/or past treatment for alcohol addiction.
-
Patients with evidence of pre-operative portal hypertension as per clinical history and abdominal/liver imaging by ultrasound techniques.
Sites will comply with any additional or more restrictive exclusion criteria locally accepted, as per centre practice.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of California. Department of Surgery, Division of Transplantation | San Francisco | California | United States | 94143 |
| 2 | The University of Chicago Medical Center | Chicago | Illinois | United States | 60637 |
| 3 | Schulze Diabetes Institute University of Minnesota Medical School | Minneapolis | Minnesota | United States | 55455 |
| 4 | Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | United States | 03756 |
| 5 | The University of Cincinnati Medical Center | Cincinnati | Ohio | United States | 45219 |
| 6 | Thomas E. Starzl Transplantation Institute University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | United States | 15213 |
| 7 | Medical University of South Carolina | Charleston | South Carolina | United States | 29425 |
| 8 | Baylor University Medical Center | Dallas | Texas | United States | 75246 |
| 9 | University of Alberta, Clinical Islet Transplant Program | Edmonton | Alberta | Canada | T6G 2C8 |
Sponsors and Collaborators
- Dompé Farmaceutici S.p.A
Investigators
- Principal Investigator: Melena Bellin, MD, Schulze Diabetes Institute; University of Minnesota Amplatz Children's Hospital
Study Documents (Full-Text)
More Information
Publications
None provided.- REP0112
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Period Title: Overall Study | ||
| STARTED | 52 | 52 |
| COMPLETED | 42 | 45 |
| NOT COMPLETED | 10 | 7 |
Baseline Characteristics
| Arm/Group Title | Reparixin | Placebo | Total |
|---|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour | Total of all reporting groups |
| Overall Participants | 50 | 52 | 102 |
| Age (Count of Participants) | |||
| <=18 years |
2
4%
|
0
0%
|
2
2%
|
| Between 18 and 65 years |
46
92%
|
52
100%
|
98
96.1%
|
| >=65 years |
2
4%
|
0
0%
|
2
2%
|
| Age (years) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [years] |
40.0
(14.4)
|
39.0
(10.0)
|
39.5
(12.2)
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
33
66%
|
38
73.1%
|
71
69.6%
|
| Male |
17
34%
|
14
26.9%
|
31
30.4%
|
| Race/Ethnicity, Customized (Count of Participants) | |||
| Hispanic or Latino |
1
2%
|
3
5.8%
|
4
3.9%
|
| Not Hispanic or Latino |
49
98%
|
49
94.2%
|
98
96.1%
|
| Region of Enrollment (participants) [Number] | |||
| Canada |
4
8%
|
3
5.8%
|
7
6.9%
|
| United States |
46
92%
|
49
94.2%
|
95
93.1%
|
Outcome Measures
| Title | Percentage of Patients Who Were Insulin Independent After Islet Autotransplantation (IAT) at Day 365±14 Days After Transplant. |
|---|---|
| Description | Insulin-independence is defined as freedom from the need to take exogenous insulin for 14 or more consecutive days, with adequate glycemic control, as defined by: a glycated hemoglobin (HbA1c) level <6.5%; fingerstick fasting blood glucose not exceeding 126 mg/dL more than three times in the past week (based on a minimum of one daily measurement; a 2 hour post-prandial blood glucose not exceeding 180 mg/dL more than four times in the past week (based on a minimum of one daily measurement); a laboratory fasting glucose in the non-diabetic range (<126 mg/dL). |
| Time Frame | day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. Eligible patients are included in this population whether or not they receive IAT. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 50 | 52 |
| Number [Percentage of participants] |
20.0
40%
|
21.2
40.8%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.542 |
| Comments | ||
| Method | Cochran-Mantel-Haenszel | |
| Comments | ||
| Method of Estimation | Estimation Parameter | t-test |
| Estimated Value | -1.2 | |
| Confidence Interval |
(2-Sided) 95% -14.3 to 000 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Area Under the Curve (AUC) for the Serum C-peptide Level at Day 75±14 After the Transplant |
|---|---|
| Description | AUC for the serum C-peptide level is calculated during the first 4 hours of an MMTT, normalized by the number of Islet Equivalent (IEQ)/kg |
| Time Frame | day 75±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. Eligible patients are included in this population whether or not they receive IAT. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 43 | 48 |
| Mean (Standard Deviation) [(ng/mL)/(IEQ/kg)*1000] |
0.5314796
(0.3520819)
|
0.6827533
(0.4769178)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.092 |
| Comments | ||
| Method | t-test, 2 sided | |
| Comments | ||
| Method of Estimation | Estimation Parameter | least square mean difference |
| Estimated Value | -0.1601778 | |
| Confidence Interval |
(2-Sided) 95% -0.3178030 to -0.0025525 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Area Under the Curve (AUC) for the Serum C-peptide Level at Day 365±14 After the Transplant |
|---|---|
| Description | AUC for the serum C-peptide level is calculated during the first 4 hours of a mixed meal tolerance test (MMTT), normalized by the number of Islet Equivalent (IEQ)/kg |
| Time Frame | day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. Eligible patients are included in this population whether or not they receive IAT |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 33 | 41 |
| Mean (Standard Deviation) [(ng/mL)/(IEQ/kg)*1000] |
0.5563432
(0.3133415)
|
0.6865954
(0.4464460)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.161 |
| Comments | ||
| Method | t-test, 2 sided | |
| Comments | ||
| Method of Estimation | Estimation Parameter | least square mean difference |
| Estimated Value | -0.1178242 | |
| Confidence Interval |
(2-Sided) 95% -0.2874310 to 0.0517825 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Average Daily Insulin Requirements at Day 75±14 After the Transplant |
|---|---|
| Description | Daily insulin is reported as IU/kg and intake averaged over the previous week. |
| Time Frame | day 75±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. Eligible patients are included in this population whether or not they receive IAT. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 44 | 49 |
| Mean (Standard Deviation) [IU/kg/day] |
0.2125
(0.1643)
|
0.2190
(0.1589)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.846 |
| Comments | ||
| Method | t-test, 2 sided | |
| Comments | ||
| Method of Estimation | Estimation Parameter | least square mean difference |
| Estimated Value | 0.0136 | |
| Confidence Interval |
(2-Sided) 95% -0.0508 to 0.0781 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Average Daily Insulin Requirements at Day 365±14 After the Transplant |
|---|---|
| Description | Daily insulin is reported as IU/kg and intake averaged over the previous week. |
| Time Frame | day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. Eligible patients are included in this population whether or not they receive IAT. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 39 | 43 |
| Mean (Standard Deviation) [IU/kg/day] |
0.1723
(0.1893)
|
0.1823
(0.1994)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.817 |
| Comments | ||
| Method | t-test, 2 sided | |
| Comments | ||
| Method of Estimation | Estimation Parameter | least square mean difference |
| Estimated Value | -0.025 | |
| Confidence Interval |
(2-Sided) 95% -0.0939 to 0.0689 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Time Course From Basal to 240 Min of Glucose Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant |
|---|---|
| Description | Data of this outcome are reported as "model estimates over all timepoints". This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=43; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal). 15 min; N=42; 46 30 min; N=40; 46 60 min; N=40; 46 90 min; N=40; 46 120 min; N=41; 46 180 min; N=40; 46 240 min; N=39; 44 |
| Time Frame | day 75±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. Eligible patients are included in this population whether or not they receive IAT |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 50 | 52 |
| Least Squares Mean (Standard Error) [mg/dL] |
157.0894
(11.98160)
|
166.5535
(11.45706)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.570 |
| Comments | ||
| Method | Mixed Models Analysis | |
| Comments | ||
| Method of Estimation | Estimation Parameter | least square mean difference |
| Estimated Value | -9.4641 | |
| Confidence Interval |
(2-Sided) 95% -42.4900 to 23.5618 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Time Course From Basal to 240 Min of Glucose Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant |
|---|---|
| Description | Data are reported as "model estimates over all timepoints" This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=34; 42 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal). 15 min; N=34; 41 30 min; N=34; 41 60 min; N=34; 41 90 min; N=34; 41 120 min; N=34; 41 180 min; N=33; 41 240 min; N=33; 41 |
| Time Frame | day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 50 | 52 |
| Least Squares Mean (Standard Error) [mg/dL] |
157.9988
(12.00455)
|
180.9442
(12.08647)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | =0.074 |
| Comments | ||
| Method | Mixed Models Analysis | |
| Comments | ||
| Method of Estimation | Estimation Parameter | least square mean difference |
| Estimated Value | -22.9454 | |
| Confidence Interval |
(2-Sided) 95% -48.1826 to 2.2918 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Time Course From Basal to 240 Min of C-peptide Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant |
|---|---|
| Description | Data are reported as "model estimates over all timepoints". This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=44; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal). 15 min; N=43; 47 30 min; N=41; 47 60 min; N=42; 47 90 min; N=42; 47 120 min; N=42; 47 180 min; N=41; 47 240 min; N=40; 44 |
| Time Frame | day 75±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 50 | 52 |
| Least Squares Mean (Standard Error) [ng/mL] |
1.8976
(0.20787)
|
2.1051
(0.20104)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | =0.358 |
| Comments | ||
| Method | Mixed Models Analysis | |
| Comments | ||
| Method of Estimation | Estimation Parameter | least square mean difference |
| Estimated Value | -0.2074 | |
| Confidence Interval |
(2-Sided) 95% -0.6538 to 0.2389 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Time Course From Basal to 240 Min of C-peptide Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant |
|---|---|
| Description | Data are reported as "model estimates over all timepoints". This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=33; 41 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal). 15 min; N=34; 41 30 min; N=34; 41 60 min; N=33; 41 90 min; N=34; 41 120 min; N=34; 41 180 min; N=33; 40 240 min; N=33; 41 |
| Time Frame | day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 50 | 52 |
| Least Squares Mean (Standard Error) [ng/mL] |
1.6052
(0.24507)
|
1.8822
(0.24763)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | =0.288 |
| Comments | ||
| Method | Mixed Models Analysis | |
| Comments | ||
| Method of Estimation | Estimation Parameter | least square mean difference |
| Estimated Value | -0.2770 | |
| Confidence Interval |
(2-Sided) 95% -0.7936 to 0.2396 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Time Course From Basal to 240 Min of Insulin Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant |
|---|---|
| Description | Data are reported as "model estimates over all timepoints". This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=43; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal). 15 min; N=43; 47 30 min; N=41; 47 60 min; N=41; 47 90 min; N=41; 47 120 min; N=42; 47 180 min; N=41; 47 240 min; N=40; 44 |
| Time Frame | day 75±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 50 | 52 |
| Least Squares Mean (Standard Error) [UIU/mL] |
23.67209
(3.497499)
|
23.57493
(3.378854)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | =0.980 |
| Comments | ||
| Method | Mixed Models Analysis | |
| Comments | ||
| Method of Estimation | Estimation Parameter | least square mean difference |
| Estimated Value | 0.09716 | |
| Confidence Interval |
(2-Sided) 95% -7.41834 to 7.61266 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Time Course From Basal to 240 Min of Insulin Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant |
|---|---|
| Description | Data are reported as "model estimates over all timepoints". This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=34; 41 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal) 15 min; N=34; 41 30 min; N=34; 41 60 min; N=34; 41 90 min; N=34; 41 120 min; N=34; 41 180 min; N=33; 41 240 min; N=33; 40 |
| Time Frame | day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 50 | 52 |
| Least Squares Mean (Standard Error) [UIU/mL] |
22.85522
(3.718512)
|
21.77905
(3.757573)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | =0.785 |
| Comments | ||
| Method | Mixed Models Analysis | |
| Comments | ||
| Method of Estimation | Estimation Parameter | least square mean difference |
| Estimated Value | 1.07617 | |
| Confidence Interval |
(2-Sided) 95% -6.76562 to 8.91796 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | β-cell Function at Day 75±14 After the Transplant |
|---|---|
| Description | This variable is assessed by β-score (assessment of β-cell function after islet transplantation). The total score is calculated on a 0-8 scoring system (higher is a better outcome) that gives 0-2 points each for: fasting plasma glucose, HbA1c, stimulated C-peptide insulin requirement subscales. The higher the total score, the better the outcome. Fasting (or before breakfast) plasma glucose (mg/dL) : ≤99, Score 2; 100-124, Score 1; ≥ 125, Score 0 (the higher the subscore the better the outcome) HbA1c (%): ≤6.1, Score 2; 6.2-6.9, Score 1; ≥ 7.0, Score 0 (the higher the subscore the better the outcome) Daily average (previous week) insulin (IU/kg/day): ---, Score 2; 0.01-0.24, Score 1; ≥ 0.25, Score 0 (the higher the subscore the better the outcome) Stimulated C-peptide (ng/mL): ≥ 0.9, Score 2; 0.3-0.89, Score 1; ≤0.3, Score 0 (the higher the subscore the better the outcome) |
| Time Frame | day 75±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. Eligible patients are included in this population whether or not they receive IAT. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 42 | 47 |
| Mean (Standard Deviation) [score on a scale] |
5.7
(1.6)
|
5.2
(1.9)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.176 |
| Comments | ||
| Method | Wilcoxon (Mann-Whitney) | |
| Comments | ||
| Title | β-cell Function at Day 365±14 After the Transplant |
|---|---|
| Description | This variable is assessed by β-score (assessment of β-cell function after islet transplantation). The total score is calculated on a 0-8 scoring system (higher is a better outcome) that gives 0-2 points each for glucose, HbA1c, stimulated C-peptide and insulin requirement subscales. The higher the total score the better the outcome. Fasting (or before breakfast) plasma glucose (mg/dL) : ≤99, Score 2; 100-124, Score 1; ≥ 125, Score 0 (the higher the subscore the better the outcome) HbA1c (%): ≤6.1, Score 2; 6.2-6.9, Score 1; ≥ 7.0, Score 0 (the higher the subscore the better the outcome) Daily average (previous week) insulin (IU/kg/day): ---, Score 2; 0.01-0.24, Score 1; ≥ 0.25, Score 0 (the higher the subscore the better the outcome) Stimulated C-peptide (ng/mL): ≥ 0.9, Score 2; 0.3-0.89, Score 1; ≤0.3, Score 0 (the higher the subscore the better the outcome) |
| Time Frame | day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. Eligible patients are included in this population whether or not they receive IAT. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 32 | 41 |
| Median (Standard Deviation) [score on a scale] |
5.9
(2.0)
|
5.4
(2.4)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.403 |
| Comments | ||
| Method | Wilcoxon (Mann-Whitney) | |
| Comments | ||
| Title | Proportion of Patients With an HbA1c <6.5% at Day 365±14 After the Transplant |
|---|---|
| Description | Percentage of patients with a glycated haemoglobin (HbA1c) <6.5% at day 365±14 after the transplant. |
| Time Frame | day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. Eligible patients are included in this population whether or not they receive IAT |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 42 | 45 |
| Number (95% Confidence Interval) [percentage of participants] |
64.3
128.6%
|
62.2
119.6%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.842 |
| Comments | ||
| Method | Chi-squared | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Treatment effect |
| Estimated Value | 2.1 | |
| Confidence Interval |
(2-Sided) 95% -18.20 to 22.33 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Cumulative Number of Severe Hypoglycemic Events From Day 75±14 to Day 365±14 After the Transplant |
|---|---|
| Description | A severe hypoglycemic event is defined as an event with one of the following symptoms: "memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms", in which the subject was unable to treat him/herself and which was associated with either a blood glucose level <54mg/dL or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration. |
| Time Frame | from day 75±14 to day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. Eligible patients are included in this population whether or not they receive IAT. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 41 | 44 |
| Mean (Standard Deviation) [number of events] |
0.1
(0.94)
|
0.0
(0.21)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.339 |
| Comments | ||
| Method | Anderson-Gill model | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
| Estimated Value | 3.21 | |
| Confidence Interval |
(2-Sided) 95% 0.29 to 34.97 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Proportion of Patients With an HbA1c <6.5% at Day 365±14 After the Transplant AND Free of Severe Hypoglycemic Events From Day 75±14 to Day 365±14 After the Transplant Inclusive |
|---|---|
| Description | Percentage of patients with an HbA1c <6.5% at day 365±14 after the transplant AND free of severe hypoglycemic events from day 75±14 to day 365±14 after the transplant inclusive.A severe hypoglycemic event is defined as an event with one of the following symptoms: "memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms", in which the subject was unable to treat him/herself and which was associated with either a blood glucose level <54mg/dL or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration. |
| Time Frame | from day 75±14 to day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. Eligible patients are included in this population whether or not they receive IAT. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 39 | 44 |
| Number (95% Confidence Interval) [percentage of participants] |
64.1
128.2%
|
59.1
113.7%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.640 |
| Comments | ||
| Method | Chi-squared | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Treatment effect |
| Estimated Value | 5.0 | |
| Confidence Interval |
(2-Sided) 95% -15.91 to 25.93 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Incidence and Severity of Adverse Events and Serious Adverse Events Throughout the Study |
|---|---|
| Description | The percentages of patients with any treatment emergent adverse events (TEAE, serious and non serious) and with serious TEAE by severity are presented. Patients with multiple events within a particular system organ class or preferred term were counted only under the category of their most severe event within that system organ class or preferred term. A serious AE was defined as any untoward medical occurrence that at any dose: Resulted in death Was life-threatening (ie, the patient was at risk of death at the time of the event) Required inpatient hospitalization or prolongation of existing hospitalization Resulted in persistent or significant disability/incapacity Was a congenital anomaly/birth defect Was an important medical event that, based upon appropriate medical judgment, may have jeopardized the patient and may have required medical or surgical intervention to prevent one of the outcomes listed above |
| Time Frame | up to day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. Eligible patients are included in this population whether or not they receive IAT. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 50 | 52 |
| TEAE- Mild events |
90.0
|
92.3
|
| TEAE - Moderate events |
90.0
|
80.8
|
| TEAE - Severe events |
64.0
|
53.8
|
| serious TEAE- Mild events |
18.0
|
23.1
|
| serious TEAE- Moderate events |
22.0
|
13.5
|
| serious TEAE- Severe events |
42.0
|
32.7
|
| Title | Proportion of Patients Falling Into One of the Following Malnutrition Risk Levels (Poor Prognosis, Significant Risk, Increased Risk, Normal) According to Pre-albumin Level at Day 75±14 After the Transplant |
|---|---|
| Description | Malnutrition risk levels are defined as: Poor prognosis = pre-albumin level <5.0 mg/dL Significant risk = pre-albumin level 5.0 to 10.9 mg/dL Increased risk = pre-albumin level 11.0 to 15.0 mg/dL Normal = pre-albumin level > 15.0 (up to 35.0) mg/dL |
| Time Frame | day 75±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 42 | 46 |
| poor prognosis |
0
|
0
|
| significant risk |
9.5
|
4.3
|
| increased risk |
45.2
|
28.3
|
| normal |
45.2
|
67.4
|
| Title | Proportion of Patients Falling Into One of the Following Malnutrition Risk Levels (Poor Prognosis, Significant Risk, Increased Risk, Normal) According to Pre-albumin Level at Day 365±14 After the Transplant |
|---|---|
| Description | Malnutrition risk levels are defined as: Poor prognosis = pre-albumin level <5.0 mg/dL Significant risk = pre-albumin level 5.0 to 10.9 mg/dL Increased risk = pre-albumin level 11.0 to 15.0 mg/dL Normal = pre-albumin level > 15.0 (up to 35.0) mg/dL |
| Time Frame | day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 40 | 44 |
| Poor prognosis |
5.0
10%
|
0
0%
|
| Significant risk |
2.5
5%
|
6.8
13.1%
|
| Increased risk |
27.5
55%
|
9.1
17.5%
|
| Normal |
65.0
130%
|
84.1
161.7%
|
| Title | Proportion of Patients by Steatorrhea Severity at Day 75±14 After the Transplant |
|---|---|
| Description | Levels of steatorrhea severity (evaluated in the 4 weeks prior to day 75±14 and 365±14), are defined as: No steatorrhea; Steatorrhea few times per week; Steatorrhea daily; Stool incontinence. |
| Time Frame | day 75±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 44 | 48 |
| no steatorrhea |
54.5
109%
|
64.6
124.2%
|
| steatorrhea few times per week |
29.5
59%
|
25.0
48.1%
|
| steatorrhea daily |
11.4
22.8%
|
6.3
12.1%
|
| stool incontinence |
4.5
9%
|
4.2
8.1%
|
| Title | Proportion of Patients by Steatorrhea Severity at Day 365±14 After the Transplant |
|---|---|
| Description | Levels of steatorrhea severity (evaluated in the 4 weeks prior to day 75±14 and 365±14), are defined as: No steatorrhea; Steatorrhea few times per week; Steatorrhea daily; Stool incontinence. |
| Time Frame | day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 42 | 46 |
| no steatorrhea |
52.4
104.8%
|
58.7
112.9%
|
| steatorrhea few times per week |
26.2
52.4%
|
19.6
37.7%
|
| steatorrhea daily |
21.4
42.8%
|
21.7
41.7%
|
| stool incontinence |
0
0%
|
0
0%
|
| Title | Cumulative Number of Episodes of Documented Asymptomatic Hypoglycemia From Day 75±14 to Day 365±14 After the Transplant |
|---|---|
| Description | The following definition applies: - Asymptomatic hypoglycemia = An event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration <70mg/dL. |
| Time Frame | from day 75±14 to day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 41 | 45 |
| Mean (Standard Deviation) [number of episodes] |
1.5
(4.3)
|
4.4
(25.6)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.448 |
| Comments | ||
| Method | Wilcoxon rank-sum test | |
| Comments | ||
| Title | Cumulative Number of Episodes of Documented Symptomatic Hypoglycemia From Day 75±14 to Day 365±14 After the Transplant |
|---|---|
| Description | The following definition applies: - Documented symptomatic hypoglycemia = An event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration <70mg/dL. |
| Time Frame | from day 75±14 to day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 41 | 45 |
| Mean (Standard Deviation) [number of episodes] |
4.6
(13.9)
|
4.8
(17.8)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.910 |
| Comments | ||
| Method | Wilcoxon rank-sum test | |
| Comments | ||
| Title | Cumulative Number of Diabetic Ketoacidosis-related Events |
|---|---|
| Description | A diabetic ketoacidosis event is defined as the presence of: hyperglycemia (blood glucose >200 mg/dL); pH <7.3 or HCO3 <15; ketones positive in the serum or urine. |
| Time Frame | from day 75±14 to day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 41 | 46 |
| Mean (Standard Deviation) [number of events] |
0.0
(0.0)
|
0.0
(0.0)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 1.000 |
| Comments | ||
| Method | Wilcoxon rank-sum test | |
| Comments | ||
| Title | Peak C-peptide at Day 75 After the Transplant |
|---|---|
| Description | Peak C-peptide (C-P) is a known predictor of Type 1 Diabetes. |
| Time Frame | Day 75±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT population: ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 44 | 48 |
| Mean (Standard Deviation) [ng/mL] |
2.640
(1.529)
|
2.900
(1.753)
|
| Title | Peak C-peptide at Day 365 After the Transplant |
|---|---|
| Description | Peak C-peptide (C-P) is a known predictor of Type 1 Diabetes. |
| Time Frame | Day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population: ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 34 | 41 |
| Mean (Standard Deviation) [ng/mL] |
2.630
(1.467)
|
3.170
(1.843)
|
| Title | Time-to-peak C-peptide at Day 75 After the Transplant |
|---|---|
| Description | The time-to-peak value in minutes was computed as the time of the peak value (HH:MM on a 24-hour clock) minus the end time of the mixed meal (HH:MM on a 24-hour clock) as recorded on the mixed meal tolerance test Case Report Form. |
| Time Frame | day 75±14 and day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population: ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 43 | 44 |
| Mean (Standard Deviation) [minutes] |
104.2
(93.6)
|
108.7
(59.4)
|
| Title | Time-to-peak C-peptide at Day 365 After the Transplant |
|---|---|
| Description | The time to peak value in minutes will be computed as the time of the peak value (HH:MM on a 24-hour clock) minus the end time of the mixed meal (HH:MM on a 24-hour clock) as recorded on the mixed meal tolerance test CRF. |
| Time Frame | Day 365±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT Population: ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 31 | 40 |
| Mean (Standard Deviation) [minutes] |
97.8
(90.9)
|
102.0
(56.2)
|
| Title | Change From Baseline in Post-transplant Alanine Aminotransferase (ALT) |
|---|---|
| Description | Data are reported as "model estimates over all timepoints". This safety parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: baseline; N=50; 52 Day 2 post-transplant; N=49; 51 Day 3 post-transplant; N=47; 50 Day 7 post-transplant; N=47; 50 Day 75 post-transplant; N=44; 47 |
| Time Frame | Baseline, Days 2, 3, 7, 75 ±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population: Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 50 | 52 |
| Least Squares Mean (Standard Error) [U/L] |
60.4105
(40.9699)
|
29.0615
(40.2724)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | =0.5018 |
| Comments | ||
| Method | Mixed Models Analysis | |
| Comments | ||
| Method of Estimation | Estimation Parameter | least square mean difference |
| Estimated Value | 31.3491 | |
| Confidence Interval |
(2-Sided) 95% -60.9980 to 123.70 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Change From Baseline in Post-transplant Aspartate Aminotransferase (AST) |
|---|---|
| Description | Data are reported as "model estimates over all timepoints". This safety parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: baseline; N=50; 52 Day 2 post-transplant; N=49; 51 Day 3 post-transplant; N=47; 50 Day 7 post-transplant; N=47; 50 Day 75 post-transplant; N=44; 47 |
| Time Frame | Baseline, Days 2, 3, 7, 75±14 after the transplant |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population: Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 50 | 52 |
| Least Squares Mean (Standard Error) [U/L] |
46.8755
(27.8248)
|
23.3301
(26.6545)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Reparixin, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | =0.4537 |
| Comments | ||
| Method | Mixed Models Analysis | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Least square mean difference |
| Estimated Value | 23.5454 | |
| Confidence Interval |
(2-Sided) 95% -38.6619 to 85.7528 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Number of Treatment Emergent Adverse Events Related to Investigational Product |
|---|---|
| Description | Treatment emergent adverse events - possibly, probably and highly probably - related to investigational product are called "Adverse reactions" (ADR). An adverse reaction is defined as any untoward medical occurrence in a patient or clinical investigation patient, which has a causal relationship with the administered medicinal product. |
| Time Frame | Throughout the study From Day -1 to hospital discharge |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population:Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 50 | 52 |
| possibly related |
20
|
28
|
| probably related |
0
|
0
|
| highly probably related |
0
|
0
|
| Title | Number of Serious Treatment Emergent Adverse Events Related to Investigational Product |
|---|---|
| Description | Serious Treatment emergent adverse events - possibly, probably and highly probably - related to investigational product are called serious "Adverse reactions". A serious adverse reaction is defined as any untoward medical occurrence with a causal relationship with the administered medicinal product, that at any dose: Resulted in death Was life-threatening (ie, the patient was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.) Required patient hospitalization or prolongation of existing hospitalization Resulted in persistent or significant disability/incapacity Was an important medical event that, based upon appropriate medical judgment, may have jeopardized the patient and may have required medical or surgical intervention to prevent one of the outcomes listed above |
| Time Frame | Throughout the study From Day -1 to hospital discharge for all adverse events, and from then to day 365 post-transplantation only for serious adverse events |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population: Safety Population consists of all randomized patients. Summarization and analysis of this population were based on treatment received. Patients randomized but not treated were analyzed in the total summary statistics only. |
| Arm/Group Title | Reparixin | Placebo |
|---|---|---|
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour |
| Measure Participants | 50 | 52 |
| possibly related |
4
|
1
|
| probably related |
0
|
0
|
| highly probably related |
0
|
0
|
Adverse Events
| Time Frame | From Day -1 to hospital discharge for all adverse events, and from then to day 365 post-transplantation only for serious adverse events. | |||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | Reparixin | Placebo | ||
| Arm/Group Description | Solution for intravenous (IV) infusion with active compound Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour | Physiologic solution Placebo: Physiologic solution administered at 0.25 mL/kg/hour | ||
All Cause Mortality |
||||
| Reparixin | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/50 (0%) | 0/52 (0%) | ||
Serious Adverse Events |
||||
| Reparixin | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 29/50 (58%) | 30/52 (57.7%) | ||
| Blood and lymphatic system disorders | ||||
| Leucocytosis | 1/50 (2%) | 1 | 1/52 (1.9%) | 2 |
| Cardiac disorders | ||||
| Sinus tachycardia | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Eye disorders | ||||
| Eye pain | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Visual impairment | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Gastrointestinal disorders | ||||
| Abdominal pain | 13/50 (26%) | 22 | 7/52 (13.5%) | 19 |
| Vomiting | 4/50 (8%) | 4 | 4/52 (7.7%) | 7 |
| Nausea | 3/50 (6%) | 4 | 4/52 (7.7%) | 10 |
| small intestinal obstruction | 2/50 (4%) | 2 | 4/52 (7.7%) | 4 |
| Diarrhoea | 0/50 (0%) | 0 | 3/52 (5.8%) | 8 |
| abdominal hernia | 1/50 (2%) | 1 | 2/52 (3.8%) | 2 |
| Colitis | 1/50 (2%) | 1 | 2/52 (3.8%) | 2 |
| Intra-abdominal fluid collection | 2/50 (4%) | 2 | 0/52 (0%) | 0 |
| Abdominal pain lower | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Ascites | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Constipation | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Enteritis | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Faecaloma | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Gastritis | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Gastrointestinal Haemorrage | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Gastrintestinal necrosis | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| impaired gastric empting | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| intestinal ischeamia | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| omental infarction | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Upper gastrointestinal haemorrhage | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| General disorders | ||||
| Pyrexia | 3/50 (6%) | 3 | 1/52 (1.9%) | 2 |
| Hernia | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Malaise | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Oedema peripheral | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Peripheral swelling | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Vascular stent occlusion | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Hepatobiliary disorders | ||||
| Hepatic function abnormal | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Portal vein thrombosis | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Infections and infestations | ||||
| Pneumonia | 3/50 (6%) | 3 | 1/52 (1.9%) | 1 |
| Urinary tract infections | 2/50 (4%) | 2 | 1/52 (1.9%) | 1 |
| Clostridium difficile infection | 2/50 (4%) | 3 | 0/52 (0%) | 0 |
| Clostridium difficile colitis | 2/50 (4%) | 2 | 0/52 (0%) | 0 |
| Postoperative wound infection | 2/50 (4%) | 2 | 0/52 (0%) | 0 |
| Sepsis | 2/50 (4%) | 2 | 0/52 (0%) | 0 |
| Gastrenteritis viral | 0/50 (0%) | 0 | 1/52 (1.9%) | 2 |
| Bacterial infection | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Biliary tract infection | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Cellulitis | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Gastroenteritis | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| gastrointestinal infection | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Influenza | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Joint abscess | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| postoperative abscess | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Urosepsis | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Viral infection | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Wound infection | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Injury, poisoning and procedural complications | ||||
| Anastomotic ulcer | 0/50 (0%) | 0 | 4/52 (7.7%) | 4 |
| Accidental overdose | 1/50 (2%) | 1 | 1/52 (1.9%) | 1 |
| Incisional hernia | 2/50 (4%) | 2 | 0/52 (0%) | 0 |
| Arterial injury | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Gastroparesis postoperative | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Post procedural haemorrhage | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Post operative hernia | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Seroma | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Vascular graft stenosis | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Wound complication | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Investigations | ||||
| Transaminases increased | 2/50 (4%) | 3 | 0/52 (0%) | 0 |
| Hepatic enzyme increased | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Metabolism and nutrition disorders | ||||
| Dehydration | 2/50 (4%) | 6 | 2/52 (3.8%) | 4 |
| Malnutrition | 1/50 (2%) | 1 | 2/52 (3.8%) | 3 |
| Hyperglycaemia | 1/50 (2%) | 1 | 1/52 (1.9%) | 1 |
| Hypoglycaemia | 0/50 (0%) | 0 | 2/52 (3.8%) | 2 |
| Diabetes mellitus inadequate control | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Failure to thrive | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Hypercalaemia | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Musculoskeletal and connective tissue disorders | ||||
| Back pain | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Osteoarthritis | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||||
| Thyroid cancer | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Nervous system disorders | ||||
| Depressed levele of consciousness | 1/50 (2%) | 1 | 1/52 (1.9%) | 1 |
| Migrane | 0/50 (0%) | 0 | 1/52 (1.9%) | 2 |
| Lethargy | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Syncope | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Psychiatric disorders | ||||
| Mental status changes | 1/50 (2%) | 2 | 0/52 (0%) | 0 |
| Confusion of state | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Renal and urinary disorders | ||||
| Acute kidney injury | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Respiratory, thoracic and mediastinal disorders | ||||
| Acute respiratory distress syndrome | 1/50 (2%) | 1 | 1/52 (1.9%) | 1 |
| Pulmonary embolism | 1/50 (2%) | 1 | 1/52 (1.9%) | 1 |
| Atelectasis | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Pleuritic pain | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| respiratory failure | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Vascular disorders | ||||
| Hypotension | 2/50 (4%) | 2 | 0/52 (0%) | 0 |
Other (Not Including Serious) Adverse Events |
||||
| Reparixin | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 46/50 (92%) | 48/52 (92.3%) | ||
| Blood and lymphatic system disorders | ||||
| Anaemia | 25/50 (50%) | 25 | 22/52 (42.3%) | 22 |
| Leukocytosis | 4/50 (8%) | 4 | 1/52 (1.9%) | 1 |
| Thrombocytosis | 3/50 (6%) | 3 | 1/52 (1.9%) | 1 |
| Iron deficiency anaemia | 1/50 (2%) | 1 | 1/52 (1.9%) | 1 |
| Coagulopathy | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Haemorragic anaemia | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Thrombocytopenia | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Cardiac disorders | ||||
| Thachycardia | 4/50 (8%) | 4 | 9/52 (17.3%) | 9 |
| Sinus tachycardia | 1/50 (2%) | 1 | 1/52 (1.9%) | 1 |
| Angina pectoris | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Endocrine disorders | ||||
| Hypothyroidism | 2/50 (4%) | 2 | 0/52 (0%) | 0 |
| Gastrointestinal disorders | ||||
| Nausea | 19/50 (38%) | 26 | 21/52 (40.4%) | 21 |
| Abdominal pain | 8/50 (16%) | 10 | 3/52 (5.8%) | 3 |
| Constipation | 11/50 (22%) | 11 | 16/52 (30.8%) | 16 |
| Vomiting | 8/50 (16%) | 8 | 7/52 (13.5%) | 7 |
| Diarrhoea | 4/50 (8%) | 4 | 3/52 (5.8%) | 3 |
| Gastrooesophageal reflux disease | 3/50 (6%) | 3 | 2/52 (3.8%) | 2 |
| Abdominal distension | 1/50 (2%) | 1 | 3/52 (5.8%) | 3 |
| Abdominal pain upper | 2/50 (4%) | 3 | 1/52 (1.9%) | 1 |
| Ascites | 1/50 (2%) | 1 | 1/52 (1.9%) | 1 |
| Dyspepsia | 1/50 (2%) | 1 | 2/52 (3.8%) | 2 |
| Flatulence | 0/50 (0%) | 0 | 3/52 (5.8%) | 3 |
| Ileus | 3/50 (6%) | 3 | 0/52 (0%) | 0 |
| Gastrointestinal haemorrhage | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Intra-abdominal haemorrhage | 2/50 (4%) | 2 | 0/52 (0%) | 0 |
| Abdominal rigidity | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Bile acid malabsorption | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Gastrointestinal pain | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Hypoaesthesia oral | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Jejunal ulcer | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| mesenteric artery trhombosis | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Peptic ulcer | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Pneumatosis intestinalis | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Stomatitis | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| General disorders | ||||
| Pyrexia | 10/50 (20%) | 13 | 10/52 (19.2%) | 11 |
| Oedema peripheral | 1/50 (2%) | 1 | 3/52 (5.8%) | 3 |
| Pain | 2/50 (4%) | 3 | 2/52 (3.8%) | 2 |
| Non-cardiac chest pain | 0/50 (0%) | 0 | 3/52 (5.8%) | 3 |
| Asthenia | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Breackthrough pain | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Chills | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Generalized oedema | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Secretion discharge | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Hepatobiliary disorders | ||||
| Portal vein thrombosis | 3/50 (6%) | 3 | 0/52 (0%) | 0 |
| Hepatitis | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Hyperbilirubinaemia | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Infections and infestations | ||||
| Urinary tract infection | 2/50 (4%) | 2 | 5/52 (9.6%) | 5 |
| Penumonia | 0/50 (0%) | 0 | 4/52 (7.7%) | 4 |
| Clostridium difficile infection | 3/50 (6%) | 3 | 2/52 (3.8%) | 2 |
| Clostridium difficile colitis | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Infection | 0/50 (0%) | 0 | 3/52 (5.8%) | 3 |
| Abdominal infection | 2/50 (4%) | 2 | 0/52 (0%) | 0 |
| Cellulitis | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Candida infection | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Escherichia urinary tract infection | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Fungal infection | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Gastroenteritis clostridial | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Genital herpes | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Respiratory moniliasis | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Urinary tract infection fungal | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Vaginal infection | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Wound infection fungal | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Injury, poisoning and procedural complications | ||||
| Procedural pain | 37/50 (74%) | 37 | 43/52 (82.7%) | 43 |
| Incision site pain | 5/50 (10%) | 7 | 2/52 (3.8%) | 3 |
| Procedural nausea | 2/50 (4%) | 2 | 4/52 (7.7%) | 4 |
| Accidental overdose | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Seroma | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Anaemia postoperative | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Procedural hypotension | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Procedural vomiting | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Wound secretion | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Investigations | ||||
| Transaminases increased | 1/50 (2%) | 1 | 1/52 (1.9%) | 1 |
| Haematocrit decreased | 2/50 (4%) | 2 | 2/52 (3.8%) | 2 |
| Haemoglobin decreased | 2/50 (4%) | 2 | 2/52 (3.8%) | 2 |
| Oxygen saturation decreased | 1/50 (2%) | 1 | 3/52 (5.8%) | 3 |
| Urin output decreased | 2/50 (4%) | 2 | 2/52 (3.8%) | 2 |
| Alanine aminotransferase increased | 1/50 (2%) | 1 | 2/52 (3.8%) | 2 |
| Aspartate aminotransferase increased | 1/50 (2%) | 1 | 2/52 (3.8%) | 2 |
| Bacterial test positive | 0/50 (0%) | 0 | 3/52 (5.8%) | 3 |
| Blood bilirubin increased | 2/50 (4%) | 2 | 1/52 (1.9%) | 1 |
| Blood potassium decreased | 2/50 (4%) | 2 | 1/52 (1.9%) | 1 |
| Platelet count decreased | 2/50 (4%) | 2 | 1/52 (1.9%) | 1 |
| Platelet count increased | 0/50 (0%) | 0 | 3/52 (5.8%) | 3 |
| White blood cell count increased | 0/50 (0%) | 0 | 3/52 (5.8%) | 3 |
| Mean arterial pressure decreased | 1/50 (2%) | 1 | 1/52 (1.9%) | 1 |
| Protein total decreased | 1/50 (2%) | 1 | 1/52 (1.9%) | 1 |
| Blood creatinin decreased | 0/50 (0%) | 0 | 1/52 (1.9%) | 2 |
| Activated partial thromboplastin time prolonged | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Blood albumin decreased | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Blood alkalyne phosphatase increased | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Blood glucose decreased | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Blood magnesium decreased | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Blood phosphorus decreased | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Blood zinc decreased | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| C-reactive protein increased | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Catheter culture positive | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Electrocardiogram QT prolonged | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Fibrin degradation products increased | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| International normalized ratio increased | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Portal vein pressure increased | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Weight decreased | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Metabolism and nutrition disorders | ||||
| Hypokalaemia | 22/50 (44%) | 23 | 19/52 (36.5%) | 22 |
| Hypomagnesaemia | 11/50 (22%) | 11 | 14/52 (26.9%) | 14 |
| Hypoglycaemia | 10/50 (20%) | 12 | 11/52 (21.2%) | 12 |
| Hypophosphataemia | 9/50 (18%) | 9 | 12/52 (23.1%) | 12 |
| Hypoalbuminaemia | 7/50 (14%) | 7 | 6/52 (11.5%) | 6 |
| Hypernatraemia | 6/50 (12%) | 6 | 4/52 (7.7%) | 4 |
| Hypocalcaemia | 4/50 (8%) | 4 | 3/52 (5.8%) | 3 |
| Hypoinsulinaemia | 2/50 (4%) | 2 | 3/52 (5.8%) | 3 |
| Malnutrition | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Fluid retention | 0/50 (0%) | 0 | 4/52 (7.7%) | 4 |
| Hyperglycaemia | 0/50 (0%) | 0 | 2/52 (3.8%) | 2 |
| Hypermagnesaemia | 2/50 (4%) | 2 | 2/52 (3.8%) | 2 |
| Hypervolaemia | 2/50 (4%) | 2 | 2/52 (3.8%) | 2 |
| Hypovolaemia | 1/50 (2%) | 1 | 2/52 (3.8%) | 2 |
| Vitamin C deficiency | 2/50 (4%) | 2 | 1/52 (1.9%) | 1 |
| Calcium deficiency | 1/50 (2%) | 1 | 1/52 (1.9%) | 1 |
| Hypercalaemia | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Vitamin A deficiency | 2/50 (4%) | 2 | 0/52 (0%) | 0 |
| Fluid overload | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Musculoskeletal and connective tissue disorders | ||||
| Muscle spasms | 1/50 (2%) | 1 | 7/52 (13.5%) | 8 |
| Back pain | 1/50 (2%) | 1 | 2/52 (3.8%) | 2 |
| Musculoskeletal pain | 0/50 (0%) | 0 | 2/52 (3.8%) | 2 |
| Arthritis | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Bursitis | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Intervertebral disk degeneration | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Muscular wickness | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Musculoskeletal chest pain | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Myofascial pain syndrome | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Nervous system disorders | ||||
| ìHeadache | 0/50 (0%) | 0 | 3/52 (5.8%) | 3 |
| Balance disorder | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Dizziness | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Hypoaesthesia | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Neuropathy peripheral | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Paraesthesia | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Somnolence | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Stupor | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Unresponsive to stimuli | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Psychiatric disorders | ||||
| Anxiety | 4/50 (8%) | 4 | 11/52 (21.2%) | 11 |
| Insomnia | 2/50 (4%) | 2 | 3/52 (5.8%) | 3 |
| Confusional state | 1/50 (2%) | 1 | 2/52 (3.8%) | 2 |
| Delirium | 0/50 (0%) | 0 | 2/52 (3.8%) | 2 |
| Depression | 0/50 (0%) | 0 | 2/52 (3.8%) | 2 |
| Hallucination | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Mental disorder | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Suicidal ideation | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Renal and urinary disorders | ||||
| Acute kidney injury | 0/50 (0%) | 0 | 2/52 (3.8%) | 2 |
| Dyisuria | 1/50 (2%) | 1 | 2/52 (3.8%) | 2 |
| Urinary retention | 0/50 (0%) | 0 | 2/52 (3.8%) | 2 |
| Bladder pain | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Bladder spasm | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Haematuria | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Respiratory, thoracic and mediastinal disorders | ||||
| Oropharyngeal pain | 3/50 (6%) | 3 | 4/52 (7.7%) | 4 |
| Pleural effusion | 2/50 (4%) | 2 | 2/52 (3.8%) | 2 |
| Pulmonary oedema | 2/50 (4%) | 2 | 2/52 (3.8%) | 2 |
| Asthma | 2/50 (4%) | 2 | 1/52 (1.9%) | 1 |
| Dyspnoea | 1/50 (2%) | 1 | 2/52 (3.8%) | 2 |
| Respiratory failure | 1/50 (2%) | 1 | 1/52 (1.9%) | 1 |
| Atelectasis | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Cough | 1/50 (2%) | 1 | 1/52 (1.9%) | 1 |
| Nasal congestion | 2/50 (4%) | 2 | 0/52 (0%) | 0 |
| Apnoea | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Dysphonia | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Pulmonary thrombosis | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Respiratory depression | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Respiratory distress | 1/50 (2%) | 1 | 0/52 (0%) | 0 |
| Skin and subcutaneous tissue disorders | ||||
| Pruritus | 7/50 (14%) | 7 | 6/52 (11.5%) | 6 |
| Hyperhidrosis | 1/50 (2%) | 1 | 1/52 (1.9%) | 1 |
| Rush | 1/50 (2%) | 1 | 1/52 (1.9%) | 1 |
| Urticaria | 0/50 (0%) | 0 | 1/52 (1.9%) | 1 |
| Vascular disorders | ||||
| Hypotension | 10/50 (20%) | 10 | 12/52 (23.1%) | 13 |
| Hypertension | 7/50 (14%) | 9 | 4/52 (7.7%) | 4 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Mauro P. Ferrari, Pharm D |
|---|---|
| Organization | Dompé |
| Phone | +3902583831 |
| info@dompe.com |
- REP0112